Clinical trials: Pre-capillary Pulmonary Hypertension
Pulmonary Hypertension
TEPH: Telaglenastat Efficacy in Pulmonary Hypertension
The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH).
- Trial name
- TEPH (NCT07223528)
- Testing
- Telaglenastat
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Chan, Stephen, MD, PhD
Pulmonary Hypertension
Acute Exposure of High Altitude on Cognitive Function
Randomized crossover Trial in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary Hypertension (CTEPH) to assess the acute response to High Altitude (2500m above sea level) on cognitive…
- Trial name
- NCT03637192
- Testing
- Low altitude: 470m above sea level, Säntis; 2500m above sea Level
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Sleep-Disordered Breathing, Pulmonary Arterial Hypertension
Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment
Evaluation of the effect of CPAP (continuous positive airway pressure ) treatment in PAH (pulmonary arterial hypertension) and CTEPH (chronic thromboembolic pulmonary hypertension) patients suffering from sleep disordered…
- Conditions
- Sleep-Disordered Breathing, Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT02583906
- Testing
- CPAP
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance
The purpose of this study is to investigate the effect of travelling to moderate altitude and of nocturnal oxygen therapy during a stay at moderate altitude on exercise performance of patients with pulmonary hypertension or with…
- Trial name
- NCT02143687
- Testing
- Moderate altitude sojourn, Low altitude sojourn, Oxygen
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
High Altitude Pulmonary Hypertension, Maximal Exercise Capacity
Maximal Exercise Capacity at 2500 m of High Altitude
The impact of hypoxia on maximal work rate during incremental ramp exercise within 3-6 hours after arriving at 2500m of high altitude in patients with precapillary pulmonary hypertension
- Trial name
- NCT05264324
- Testing
- Maximal Exercise Capacity
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Hypertension, Precapillary Pulmonary Hypertension
Digital Assessment of Real-World Walking Activity in Pulmonary Hypertension: A Prospective Multicenter Trial
The goal of this observational study is to validate digital mobility outcomes for monitoring the treatment and disease progression in adult patients with pulmonary hypertension.
- Conditions
- Pulmonary Hypertension, Precapillary Pulmonary Hypertension, Right Heart Catheterisation, Digital Mobility Outcomes
- Trial name
- NCT07137260
- Testing
- Accelerometer (measurement of walking activity)
- Where
- 4 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Simon Jäger
High Altitude Pulmonary Hypertension, Sleep
Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension
The impact of hypoxia at 2500m of high altitude on sleep in patients with precapillary pulmonary hypertension
- Trial name
- NCT05089487
- Testing
- Nocturnal rest (sleep study)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FiO2:15.1, equivalent to 2500m above sea level) on pulmonary artery pressure and right heart…
- Trial name
- NCT03637140
- Testing
- Simulated Altitude (FiO2: 15.1%)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Hypertension Associated With Connective Tissue Disease
VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension
Sildenafil is a selective pulmonary vasodilator; in patients with a special kind of pulmonary hypertension it is approved for treatment.
- Trial name
- SIL-REACT (NCT01889966)
- Testing
- Sildenafil
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Kerckhoff Heart Center
Pulmonary Hypertension
Hemodynamic Effect of Nasal High-flow in Patients Suspected or Followed for a Precapillary Pulmonary Hypertension
In this study, the investigators aim to describe the hemodynamic consequences of nasal high-flow measured during right heart catheterization and echocardiography.
- Trial name
- HighFlowHD (NCT06079151)
- Testing
- Nasal high-flow
- Where
- France
- Volunteers
- 20 people
- Sponsor
- ADIR Association
Pulmonary Hypertension
Acute Exposure to High Altitude on Exercise Capacity
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) in constant loaded exercise capacity.
- Trial name
- NCT03637153
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.
The purpose of this study is to determine if patients with pulmonary hypertension and mildly elevated heart pressure known as PCWP will exhibit different patterns on echocardiography and that these patterns will predict treatment…
- Trial name
- LV strain (NCT01800292)
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Hypertension
Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.
- Trial name
- MELODY-1 (NCT02070991)
- Testing
- Macitentan
- Where
- 32 sites in United States, Austria and 9 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction
- Trial name
- NCT07123779
- Testing
- HS235
- Where
- 3 sites in United States
- Volunteers
- 126 people
- Sponsor
- 35Pharma Inc., a GSK company
Pulmonary Hypertension, Heart Failure
Study for Evaluation of Safety and Efficacy of PADN to Treat Combined Post- and Pre- Capillary Pulmonary Hypertension Associated With Chronic Heart Failure（PADN-CpcPH-PILOT）
The goal of this pilot study is to evaluate the safety and efficacy of pulmonary artery denervation (PADN) in Combined Post- and Pre- Capillary Pulmonary Hypertension Associated with Chronic Heart Failure.
- Trial name
- NCT05996562
- Testing
- Pulmonary Artery Denervation
- Where
- 7 sites in Georgia, Italy and 3 more
- Volunteers
- 30 people
- Sponsor
- Pulnovo Medical (Wuxi) Co., Ltd.
Pulmonary Hypertension
Acute Exposure of Simulated Hypoxia on ECG and Non-invasive Blood Pressure
Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to simulated altitude (FIO2: 15.1% = equivalent to 2500m above sea level) on ECG repolarizations and non-invasive blood…
- Trial name
- NCT03581851
- Testing
- Simulated Altitude: (FiO2: 15.1)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pre-capillary Pulmonary Hypertension
Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension
This study aims to understand how blood cell (including peripheral blood mononuclear cells ((PBMCs) or platelets) function and oxidative stress can help physicians detect and predict the course of pre-capillary pulmonary…
- Trial name
- NCT07176260
- Testing
- Patients with pre-Capillary pulmonary hypertension
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and…
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases
- Trial name
- The PULSE-LHD (NCT07214376)
- Testing
- Pulmonary Artery Denervation (PADN)
- Where
- 18 sites in United States, China
- Volunteers
- 750 people
- Sponsor
- Pulnovo Medical, Inc.
Pulmonary Hypertension
Acute Exposure to High Altitude on Blood and Tissue Oxygenation (ABGA, NIRS)
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) on blood and tissue oxygenation (ABGA, NIRS).
- Trial name
- NCT03600415
- Testing
- Low altitude: 470m above sea level, Säntis; 2500m above sea level
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich